Lung Cancer
Lung Cancer
Advertisement
Laura LitwinMesothelioma | July 8, 2025
Malignant peritoneal mesothelioma is a rare disease with unspecific abdominal symptoms, often diagnosed at an advanced stage.
Laura LitwinLung Cancer | July 7, 2025
The study examined the effectiveness of various interventions aimed at increasing lung cancer screening uptake rates.
Sanjay Juneja, MDLung Cancer | June 27, 2025
The forum covered critical updates in the fields of NSCLC, SCLC, immunotherapy effectiveness, and recent trial updates.
Raymond Osarogiagbon, MDASCO 2025 | June 26, 2025
Dr. Osarogiagbon shared insights on findings from the incidental lung nodule program and lung cancer screening program.
Lung Cancers Today EditorsLung Cancer | June 26, 2025
Amivantamab plus lazertinib showed a statistically significant improvement in OS compared with osimertinib.
Lung Cancers Today EditorsLung Cancer | June 26, 2025
The study, which expanded on phase 3 ADAURA, compared treatment with neoadjuvant osimertinib with or without chemotherapy.
Lung Cancers Today EditorsLung Cancer | June 26, 2025
Results demonstrated extended median progression-free survival by nearly 9 months versus standard of care.
Lung Cancers Today EditorsLung Cancer | June 25, 2025
The updated data showed an overall survival benefit with osimertinib for treating EGFR-mutated NSCLC.
Lung Cancers Today EditorsLung Cancer | June 24, 2025
The trial compared the combination with chemotherapy alone in patients with EGFR exon 20 insertion-mutated advanced NSCLC.
Jorge Nieva, MDASCO 2025 | June 30, 2025
Jorge Nieva, MD, discusses a recent study that evaluated the impact of circadian rhythms on the efficacy of immunotherapy.
Coral Olazagasti, MDASCO 2025 | June 24, 2025
Coral Olazagasti, MD, reflects on ASCO 2025 updates and the importance of bringing this news back to patients in the clinic.
Cheryl Czerlanis, MDASCO 2025 | June 24, 2025
Cheryl Czerlanis, MD, shares insights from her ASCO 2025 presentation on the topic.
Molly Li, MBBSASCO 2025 | June 24, 2025
The study participants include those who have had at least one first-degree relative diagnosed with lung cancer.
Laura LitwinNon-Small Cell Lung Cancer | June 24, 2025
The organization also granted priority review, breakthrough designation, and orphan drug designation to the application.
Matthew Smeltzer, PhDASCO 2025 | June 20, 2025
The study compared results from North America with global results by high-income and low- or middle-income countries.
Cheryl Czerlanis, MDASCO 2025 | June 19, 2025
Cheryl Czerlanis, MD, shares insights from the session on lung cancer screening that she chaired at ASCO 2025.
Shriya GargASCO 2025 | June 3, 2025
Palliative care researchers discuss differences in lung cancer treatment disparities across Hispanic patient subgroups.
Helena Yu, MDASCO 2025 | June 6, 2025
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
Coral Olazagasti, MDASCO 2025 | June 2, 2025
Coral Olazagasti, MD, and Maria Velez, MD, MS, reflect on the opportunities at the ASCO Annual Meeting.
Coral Olazagasti, MDConference Coverage | June 1, 2025
Coral Olazagasti, MD, shares why the ASCO Annual Meeting is a critical time to bring the field together.
Advertisement